1 / 7

Cell Therapy in CV Disease: Future Directions

Cell Therapy in CV Disease: Future Directions. Cardiac renewal: Is the goal in sight?. “Remaining young at heart is a desirable but elusive goal. Myocyte regeneration may accomplish just that.

sahara
Télécharger la présentation

Cell Therapy in CV Disease: Future Directions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cell Therapy in CV Disease:Future Directions

  2. Cardiac renewal: Is the goal in sight? “Remaining young at heart is a desirable but elusive goal. Myocyte regeneration may accomplish just that. Continuous cell renewal in adult myocardium was thought to be impossible; multipotent stem cells may be able to renew myocardium and, under certain circumstances, can be coaxed to repair the broken heart after infarction.” Anversa P, Nadal-Ginard B et al. Nature. 2002;415:240-3.

  3. Stem cell therapy: More questions than answers? Timing of delivery Acute vs chronic Routes of delivery Surgical vs percutaneous ? Cell type and marker Myoblast vs BM CD 34/ AC133/ SP Target patient population Best criteria Cell origin Embryonic vs adult BM vs peripheral Culture expanded vs fresh Dose Dose response Courtesy of Timothy Henry, MD.

  4. CCTRN: Addressing gaps in the knowledge base NHLBI Cardiovascular Cell Therapy Research Network, established January 2007 Universityof Florida MHIU of Minn VanderbiltUniversity Network DCC Universityof Texas Texas Heart Institute ClevelandClinic DCC = Data Coordinating CenterMHI = Minneapolis Heart Institute Nat Clin Pract Cardiovasc Med. 2007;4:403.

  5. CCTRN: Goal and initial phase I/II clinical trials Goal:Accelerate research into use of cell-based therapies in management of CV diseases TIME Effect of timing of post-MI BMC administration on measures of LV function Late TIME Effect of late (2-3 weeks) post-MI BMC administration on measures of LV function FOCUS Effect of transmyocardial BMC administration on measures of LV function in patients with chronic IHD Nat Clin Pract Cardiovasc Med. 2007;4:403.

  6. CCTRN: Timeline of trials Year 01 Year 02 Year 03 Year 04 Year 05 Protocol 1 Development PRC DSMB Review Protocol 1 Protocol 2 Development PRC DSMB Review Protocol 2 Protocol 3 Development PRC DSMB Review Protocol 3 Courtesy Timothy Henry, MD.

  7. Summary • Current clinical efforts have focused in three overlapping areas: • Repair of myocardium after MI • Reconstitution of myocardium in setting of chronic HF • Therapeutic angiogenesis • Promising early clinical experience with BMC, endothelial cells, and skeletal myoblasts • Numerous questions regarding techniques and mechanism of benefit remain • Ongoing trials by the NHLBI CCTRN and other research groups should provide insight

More Related